Crispr Therapeutics, a Basel, Switzerland-based gene-editing company, raised an additional $38m in the second close of its Series B financing.
This further investment brought the total Series B financing round to nearly $140m.
This second closing included Franklin Templeton Investments, New Leaf Venture Partners, funds advised by Clough Capital Partners L.P. and Wellington Capital Management L.L.P., and other undisclosed funds specializing in life sciences. They add to previous Series B backers Vertex Pharmaceuticals, and Bayer Global Investments, an affiliate of Bayer AG.
The company plans to use the proceeds to advance current and future programs to the clinic and to expand its research and development organization in Cambridge, Massachusetts.
Led by Dr. Rodger Novak, Chief Executive Officer, Crispr Therapeutics is a biopharmaceutical company focused on translating CRISPR/Cas9 gene-editing technology into medicines for serious diseases, based on foundational patent estate licensed from scientific founder Emmanuelle Charpentier, Ph.D. (who co-invented the application of CRISPR/Cas9 for gene editing).
To develop therapeutics in diseases with high unmet need, Crispr has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals.